Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study
详细信息 查看全文
- 作者：Terence A. Kettera ; tketter@stanford.edu" class="auth_mail" title="E-mail the corresponding author ; Jess Amchinb ; Mark A. Fryec ; Nicholas Grossb
- 关键词：Bipolar depression ; Bipolar I disorder ; Armodafinil ; Long-term safety ; Wakefulness
- 刊名：Journal of Affective Disorders
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：197
- 期：Complete
- 页码：51-57
- 全文大小：411 K
文摘
- class="listitem" id="list_li0005">
- class="label">•
Safe, well-tolerated treatments for bipolar I depression are limited.
- class="label">•
Over 6 months, open-label adjunctive armodafinil was generally safe and well tolerated.
- class="label">•
Mean measures for emergence of mania, suicidality, anxiety, or insomnia did not worsen.
- class="label">•
Results suggest a positive risk profile of adjunctive armodafinil in bipolar I depression.
- class="label">•
Adjunctive armodafinil efficacy remains to be established, and it does not have an FDA indication for bipolar I depression.